Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Year
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. reported growth YoY (%) (%)
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: 1.0% in FY2025, down 13.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Delstrigo | 306 | 249 | 23 | 56 | 56 | 1 | 250 | 193 | 29”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.0% | -13.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 14.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.